Infection最新文献

{"title":"Transitional care after hospitalization for sepsis in Germany- results from the population-based AVENIR cohort study.","authors":"Thomas Ruhnke, Josephine Storch, Antje Freytag, Norman Rose, Aurelia Kimmig, Patrik Dröge, Lisa Wedekind, Christian Günster, Ludwig Goldhahn, Enno Swart, Mathias W Pletz, Konrad Reinhart, Peter Schlattmann, Carolin Fleischmann-Struzek","doi":"10.1007/s15010-025-02589-7","DOIUrl":"https://doi.org/10.1007/s15010-025-02589-7","url":null,"abstract":"<p><strong>Purpose: </strong>Sepsis survivorship is associated with significant long-term morbidity, mortality and health care utilization. Transitional care between inpatient and follow-up care is crucial, but insufficiently understood. We investigated health care utilization in sepsis survivors 90 days post-discharge, comparing translational care during 2016-2019 vs. 2020 in the first year of the pandemic.</p><p><strong>Methods: </strong>This retrospective cohort study used nationwide health claims data of the \"AOK- die Gesundheitskasse\". Sepsis patients with inpatient treatment in 2016-2019 were identified using explicit ICD-10 codes for sepsis and codes for organ dysfunction. A second sepsis patient cohort was identified in 2020, which included also explicitly defined sepsis patients as well as patients with COVID-19 and Influenza with evidence of organ dysfunction. Among survivors, health care utilization in the 90 days post-discharge was assessed and first health service provider contacts were visualized using Sankey diagrams.</p><p><strong>Results: </strong>Among 234,874 sepsis survivors in 2016-2019, 94.4% were treated by a general practitioner, 47.7% had ≥ 1 hospital readmission and 42.8% of patients had ≥ 1 emergency treatment 90 days post-sepsis. Nearly all patients had prompt health service provider contacts in that time frame, with physicians in the outpatient sector being the most common first and second health service provider contacts. In the 2020 cohort (n = 69,432 survivors), more patients died without follow-up contact. Additionally, the latency to the first and second health service provider contacts were elevated compared to 2016-2019.</p><p><strong>Discussion: </strong>Sepsis survivors receive early, high-frequency follow-up care in the inpatient and outpatient sector. This may be an opportunity to implement early screening for sequelae and targeted therapies.</p>","PeriodicalId":13600,"journal":{"name":"Infection","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144583779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bridging continents: postgraduate infectious diseases training programs from central Europe to Southeast Asia.","authors":"Selcen Öncü, Hakan Erdem, Zeliha Kocak Tufan, Seif Salim Al-Abri, Muna Al Maslamani, Jamal Wadi Alramahi, Sinan Alrifai, Ahmed Alsuwaidi, Altaf Ahmed, Rusmir Baljic, Bojana Beović, Rok Civljak, Amangul Duisenova, Dilruba Garashova, Krsto Grozdanovski, Arjan Harxhi, Tiberiu Holban, Souha Kanj, Suresh Kumar, Ainura Kutmanova, Masoud Mardani, Ziad Ahmed Memish, Egídia Gabriela Miftode, Sadie Namani, Serkan Öncü, Michael M Petrov, Tomislav Preveden, Natalia Pshenichnaya, Bilal Ahmad Rahimi, Abdurashid Oblokulov, Yesim Taşova, Sotirios Tsiodras, George M Varghese","doi":"10.1007/s15010-025-02597-7","DOIUrl":"https://doi.org/10.1007/s15010-025-02597-7","url":null,"abstract":"<p><strong>Purpose: </strong>Increasing travel, climate change, spread of antimicrobial resistance and pandemics increased the need for well-trained infectious diseases (ID) specialists and qualified ID specialist training for protecting public health all over the world. In this study, we aimed to provide a comprehensive overview of ID specialty training programs for standardization and quality improvement in a large geographical area.</p><p><strong>Methods: </strong>We conducted a cross-sectional study among national respondents of 29 countries [Central Asia (Azerbaijan, Uzbekistan, the Kyrgyz Republic, Kazakhstan), the Middle East (Iran, Saudi Arabia, Jordan, Iraq, Oman, the United Arab Emirates, Qatar, Lebanon), Southeast Europe (Albania, Greece, Kosovo, Slovenia, Bosnia and Herzegovina, Serbia, the Republic of North Macedonia, Croatia), Eastern Europe (Russia, Moldova, Romania, Bulgaria), South Asia (India, Pakistan, Afghanistan), Southeast Asia (Malaysia), Türkiye] to evaluate the structure and components of ID training programs.</p><p><strong>Results: </strong>In this study, structural variability in ID training programs was notable. 65.5% of the countries offered independent specialty program, 59% of the countries reported a required exam for entry into the ID specialization. Nearly all of the countries had a formal training curriculum; written exams were the most common used assessment method.</p><p><strong>Conclusion: </strong>This study provides a comprehensive overview of ID specialty training across diverse regions, highlighting major structural differences in curricula, training duration, and national standards. Its broad geographic scope and contributions from actively engaged ID educators offer a unique global perspective. The findings underscore the urgent need for harmonized training frameworks, the strengthening of national curricula, and the promotion of international collaboration and inclusive strategies, all essential for developing a skilled, competent and resilient global ID workforce.</p>","PeriodicalId":13600,"journal":{"name":"Infection","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144583778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Two novel lytic bacteriophages with antibiofilm activity against carbapenem-resistant Klebsiella pneumoniae infections.","authors":"Jinghan Zhang, Xiaoxiao Sun, Ping Zeng, Lianwei Ye, Ning Dong, Zhuangzhuang Gao, Mengtian Jiang, Si-Yue Chen, Cengceng Huang, Wentao Chen, Peng Lu, Sharon Shui Yee Leung, Sheng Chen, Qipeng Cheng","doi":"10.1007/s15010-025-02599-5","DOIUrl":"https://doi.org/10.1007/s15010-025-02599-5","url":null,"abstract":"<p><p>Carbapenem-resistant Klebsiella pneumoniae (CRKP) poses a major challenge in clinical settings due to high morbidity, mortality, and limited treatment options. In response, phage therapy has reemerged as a promising alternative to conventional antibiotics. In this study, two lytic bacteriophages, Kpn_PImp2 and Kpn_PImp3, were isolated from urban sewage, a rich source of phages owing to its diverse microbial community. These phages demonstrated remarkable pH stability and thermostability, ensuring their activity under a variety of environmental and physiological conditions. Genomic analysis suggests that both phages likely belong to the Webervirus genus within the Caudoviricetes class, characterized by tailed phages with double-stranded DNA. Importantly, neither phage harbors lysogenic, toxin, nor antimicrobial resistance genes, affirming their safety for therapeutic applications. Comparative studies of tail fiber proteins, which play a crucial role in host specificity, indicate that structural variations may account for the distinct host ranges of Kpn_PImp2 and Kpn_PImp3. Moreover, both phages exhibited the ability to inhibit and disrupt biofilm formation, a key factor in CRKP persistence and resistance. Their biofilm-disrupting properties could potentially enhance the penetration and efficacy of antibiotics in combination therapies. The in vivo efficacy of these phages was further validated using the Galleria mellonella infection model, where treatment led to a significant reduction in larval mortality. However, a cocktail combining both phages did not show synergistic benefits over monophage therapy, likely due to shared host-cell receptors. These findings highlight Kpn_PImp2 and Kpn_PImp3 as promising candidates for phage therapy against CRKP, warranting further research into resistance mechanisms, delivery methods, and combination therapies to fully realize their therapeutic potential. This study also expands the bacteriophage resources against K. pneumoniae and provides valuable insights for phage-based treatments.</p>","PeriodicalId":13600,"journal":{"name":"Infection","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144575332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trough concentrations of cabotegravir and rilpivirine and their association with detectable viral load in people with HIV on long-acting treatment.","authors":"Sebastian Noe, Ulrich Seybold, Farhad Schabaz, Ariane von Krosigk, Carmen Wiese, Eva Wolf, Celia Jonsson-Oldenbüttel, Anna Ivanova","doi":"10.1007/s15010-025-02577-x","DOIUrl":"https://doi.org/10.1007/s15010-025-02577-x","url":null,"abstract":"<p><strong>Background: </strong>Cabotegravir (CAB) and rilpivirine (RPV) constitute the first complete non-oral ART regimen for HIV-1 treatment. Due to virologic failure (VF) with resistance in clinical trials, concerns persist regarding broader use in clinical practice. In particular, the role of trough drug concentrations in relation to viremia and VF remains unclear. This study explored the association between CAB and RPV trough concentrations in a retrospective, single-center study.</p><p><strong>Methods: </strong>We retrospectively analyzed data from the HIV research and clinical care center MVZ München am Goetheplatz, Germany. Inclusion criteria were CAB and RPV long-acting therapy every 8 weeks without additional ART and availability of drug concentrations within 7 days before the next administration. A modified Wilcoxon test assessed differences in concentrations between samples with HIV-1 RNA < 20 vs. ≥20 copies/mL. Odds ratios (ORs) were estimated using generalized estimation equation (GEE) models, and ROC analysis identified potential alternative drug concentration thresholds.</p><p><strong>Findings: </strong>A total of 737 samples from 185 individuals were included. Median CAB concentrations were 1,480 µg/L (IQR: 1,097-1,955) vs. 1,180 µg/L (879-1,570) for samples with HIV-1 RNA levels < 20 copies/mL vs. ≥ 20 copies/mL, respectively (p = 0.001); for RPV, 77 µg/L (53-107) vs. 63 µg/L (47-87) (p = 0.001). Using ROC-derived thresholds, low concentrations of CAB (< 1,240 µg/L) or RPV (< 76 µg/L) were found in 11.5% and 25.4% of samples, respectively, and associated with ORs of 2.4 (1.5-4.0) and 2.3 (1.4-3.8) for HIV-1 RNA ≥ 20 copies/mL.</p><p><strong>Interpretation: </strong>Lower CAB and RPV concentrations were associated with viremia, particularly using the ROC-derived thresholds. Among individuals with VF and available drug concentration data, 87.5% had at least one drug below these thresholds. Further research on therapeutic drug monitoring is warranted.</p>","PeriodicalId":13600,"journal":{"name":"Infection","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144560046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current trends on antifungal prophylaxis in solid organ transplantation: a study from ESCMID-EFISG, ESCMID-ESGICH, SITA, and SEIMC-GESITRA-IC.","authors":"Jon Salmanton-García, Alessandro Giacinta, Maddalena Giannella, Antonio Vena, Patricia Muñoz, Oliver A Cornely, Maricela Valerio","doi":"10.1007/s15010-025-02575-z","DOIUrl":"https://doi.org/10.1007/s15010-025-02575-z","url":null,"abstract":"<p><strong>Introduction: </strong>Invasive fungal diseases (IFD) present serious risks to solid organ transplant recipients, particularly in the first 180 days post-transplant. Existing European and US guidelines offer limited evidence, prompting a shift away from universal prophylaxis due to adverse effects, drug-interactions, and costs. This study investigates antifungal prophylaxis practices in transplant centers to guide IFD management.</p><p><strong>Methods: </strong>From May 2023 to May 2024, tertiary care institutions completed an online survey on antifungal prophylaxis post-transplant. Data included transplant volumes, IFD incidence by pathogen, and prophylactic strategies.</p><p><strong>Results: </strong>Responses from 64 centers in 32 countries, mainly in Europe, highlighted kidney and liver as the most common transplants. Prophylaxis was universal in lung transplants and common in liver, bowel, and heart transplants, often triggered by reintervention or Candida spp. colonization. Preferred agents included liposomal amphotericin B and fluconazole.</p><p><strong>Conclusions: </strong>This global survey reveals substantial variation in antifungal prophylaxis practices among solid organ transplant centers, driven by a lack of standardized, evidence-based guidelines. Our findings underscore the urgent need for harmonized recommendations that reflect evolving fungal epidemiology, improved diagnostics, and new antifungal agents.</p>","PeriodicalId":13600,"journal":{"name":"Infection","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144560045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing upper respiratory tract infection detection: exploring qPCR negative respiratory samples using targeted next-generation sequencing.","authors":"Zhixia Gu, Tingting Liu, Jun Li, Chuan Song, Xinlong Wang, Ying Tang, Mo Du, Yuhai Bi, Yuanyuan Zhang, Ronghua Jin, Rui Song","doi":"10.1007/s15010-025-02578-w","DOIUrl":"https://doi.org/10.1007/s15010-025-02578-w","url":null,"abstract":"<p><strong>Introduction: </strong>Respiratory infections re-emerge unpredictably. Rapid pathogen identification is crucial for effective targeted therapy.</p><p><strong>Methods: </strong>From November 15, 2023, to December 15, 2023, 574 respiratory tract samples (nasopharyngeal and oropharyngeal swabs) were collected at Beijing Ditan Hospital and Beijing Haidian Hospital. Targeted next-generation sequencing (tNGS) was further used to examine the respiratory samples identified as unfavorable by quantitative real-time PCR (qPCR).</p><p><strong>Results: </strong>Using qPCR testing, 368 out of 574 samples (64.1%) were positive, while 206 samples (35.9%) showed no pathogen. TNGS further found that 167 out of these 206 cases (81.1%) had pathogens detected, with 58 different pathogens identified. The most frequent viruses, bacteria, and fungi were H3N2 (n = 73), Streptococcus pneumoniae (S. pneumoniae) (n = 18), Staphylococcus aureus (S. aureus) (n = 18), and Candida albicans (C. albicans) (n = 17). There were 102 cases of mixed infections, among which H3N2 appeared most frequently (51/102, 50%), and coinfections often involved Human betaherpesvirus 7 and S. aureus. In 20 cases where antibiotic resistance genes (ARGs) were detected, four were infected with H3N2. Among these, TEM and tetB were associated with Acinetobacter baumannii, APH was associated with Stenotrophomonas maltophilia, and the remaining resistance genes were linked to S. pneumoniae.</p><p><strong>Conclusion: </strong>TNGS is more sensitive than qPCR for detecting pathogens, which is crucial for identifying prevalent and harmful ones like H3N2, S. pneumoniae, and S. aureus. Its integration into routine clinical testing is recommended, though more research is needed for clear guidelines.</p>","PeriodicalId":13600,"journal":{"name":"Infection","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144540069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of antibiotic therapy on clinical outcome in patients hospitalized with moderate COVID-19 disease: a prospective multi-center cohort study.","authors":"Anette Friedrichs, Roman Wenz, Daniel Pape, Katharina S Appel, Thomas Bahmer, Karsten Becker, Sven Bercker, Sabine Blaschke, Josephine Braunsteiner, Jana Butzmann, Egdar Dahl, Johanna Erber, Lisa Fricke, Ramsia Geisler, Siri Göpel, Andreas Güldner, Marina Hagen, Axel Hamprecht, Stefan Hansch, Peter U Heuschmann, Sina Hopff, Björn-Erik Ole Jensen, Nadja Käding, Julia Koepsell, Carolin E M Koll, Marcin Krawczyk, Thomas Lücke, Patrick Meybohm, Milena Milovanovic, Lazar Mitrov, Carolin Nürnberger, Christoph Römmele, Margarete Scherer, Lena Schmidbauer, Melanie Stecher, Phil-Robin Tepasse, Andreas Teufel, Jörg Janne Vehreschild, Christof Winter, Oliver Witzke, Christoph Wyen, Frank Hanses, Amke Caliebe","doi":"10.1007/s15010-025-02590-0","DOIUrl":"https://doi.org/10.1007/s15010-025-02590-0","url":null,"abstract":"<p><strong>Purpose: </strong>The benefit of antibiotic treatment (ABT) for patients with moderate COVID-19 is unclear and overtreatment poses the risk of adverse effects such as Clostridioides difficile infection and antibiotic resistance. This multi-center study compares health status improvement between patients with and without ABT at hospital admission.</p><p><strong>Methods: </strong>Between March 2020 and May 2023, hospitalized adults with confirmed SARS-CoV-2 infection were recruited from the German National Pandemic Cohort Network (NAPKON), which includes patients from various hospitals across Germany. The study population included patients with moderate or severe COVID-19 at baseline. The primary objective was to compare health improvement or decline after two weeks between patients who received ABT at baseline and those who did not in the moderate COVID-19 population. The statistical analysis adjusted for confounders such as gender, age, vaccination status, clinical condition, and comorbidities. The severe COVID-19 population was investigated as a secondary objective.</p><p><strong>Results: </strong>A total of 1,317 patients (median age 59 years; 38% women) were eligible for analysis, of whom 1,149 had moderate and 168 severe COVID-19 disease. ABT for pneumonia was administered to 467 patients with moderate and 117 with severe COVID-19. ABT at baseline was significantly associated with a higher deterioration rate after two weeks in patients with moderate COVID-19 (ABT: 292 improvement, 61 deterioration; no ABT: 429 improvement, 14 deterioration). A similar result was obtained in the multiple regression analysis where an odds ratio of 5.00 (95% confidence interval: 2.50 - 10.93) for ABT was observed.</p><p><strong>Conclusion: </strong>We found no benefit of antibiotic therapy in patients with moderate COVID-19. Use of ABT was associated with a higher likelihood of clinical deterioration.</p>","PeriodicalId":13600,"journal":{"name":"Infection","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144496137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the associations among asthma, asthma control and long COVID in U.S. adults.","authors":"Chun-Tse Hung, Yu-Chien Hung, Chi-Won Suk, Chung-Hsuen Wu","doi":"10.1007/s15010-025-02588-8","DOIUrl":"https://doi.org/10.1007/s15010-025-02588-8","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to evaluate (1) the association between asthma and long COVID among U.S. adults and (2) the association between asthma control and long COVID among U.S. adults with asthma.</p><p><strong>Methods: </strong>Data from the 2023 National Health Interview Survey were used. Adults aged ≥ 18 years were included. Asthma control was measured by the history of asthma attacks and emergency room (ER) visits for asthma. Multivariable logistic regression models were used to evaluate the associations. A sensitivity analysis was performed by stratifying long COVID severity.</p><p><strong>Results: </strong>A total of 258,237,552 adults were included in this study. The prevalence of long COVID among U.S. adults in 2023 was 8.2%. When stratified by the presence of asthma, the prevalence was 15.2% for those with asthma and 7.6% for those without asthma (P < 0.01). After adjusting for covariates, adults with asthma had higher odds of long COVID than those without asthma (OR, 1.58; 95% CI, 1.37-1.83). This association was consistent across long COVID severity levels. Poor asthma control was associated with increased odds of long COVID (asthma attacks: OR, 1.47; 95% CI, 1.09-1.97; ER visits for asthma: OR, 1.52; 95% CI, 1.02-2.27).</p><p><strong>Conclusion: </strong>Asthma was associated with increased odds of long COVID. Patients with poorly controlled asthma were associated with increased odds of long COVID. From a clinical perspective, it is crucial to proactively identify patients with asthma at increased risk of long COVID, especially those with certain comorbidities. Future research on specific symptoms and the duration of long COVID among patients with asthma will benefit clinical practice.</p>","PeriodicalId":13600,"journal":{"name":"Infection","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144484176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Experience of use of dalbavancin for the treatment of unlicensed indications in a UK tertiary infectious diseases setting.","authors":"Christopher A Darlow, Joseph Parsons, Danielle Lucy, Ang Li, Libuse Ratcliffe, Stacy Todd, Nicholas Wong","doi":"10.1007/s15010-025-02585-x","DOIUrl":"https://doi.org/10.1007/s15010-025-02585-x","url":null,"abstract":"<p><strong>Background: </strong>Dalbavancin is a long-acting lipoglycopeptide with Gram-positive activity, licensed for the treatment of acute bacterial skin and skin-structure infections (ABSSSIs), although off-licence use is increasingly prevalent. We describe our experience in Liverpool of using dalbavancin for off-licence indications and as a risk-reduction strategy in patients at risk of premature hospital discharge.</p><p><strong>Methods: </strong>Patients receiving dalbavancin in the period 1/9/2020-30/4/2024 in Liverpool were identified. Data was extracted by review of patient notes. Primary outcomes were clinical success (resolution of infection without re-admission or further antibiotics) and 90-day mortality.</p><p><strong>Results: </strong>Ninety-five individual dalbavancin courses were identified. 24/95 were for licensed indications (i.e., ABSSSI without bacteraemia). Off-licence indications included bone and joint infections (BJIs) (30/95), infective endocarditis (IE) (13/95) and Staphylococcus aureus bacteraemia (SAB) (27/95). The clinical success rate and 90-day mortality for ABSSSI without bacteraemia were 91.67% and 4.17%, respectively. BJI without bacteraemia and SAB outcomes were similar (p > 0.999). However, IE had worse rates of clinical success (61.5%, p = 0.072) and 90-day mortality (30.8%, p = 0.042). 10/18 PWIDs who were prematurely discharged achieved clinical success; 17/18 were alive at 90 days.</p><p><strong>Conclusion: </strong>The data in this retrospective analysis adds to the growing body of evidence that dalbavancin is safe and effective for the treatment of BJIs and SABs. It also reinforces the uncertainty in the literature over the efficacy of use in IE. Additionally, these data demonstrate that dalbavancin may be used successfully as a risk mitigation strategy for PWIDs who may be prematurely discharged from an inpatient stay.</p>","PeriodicalId":13600,"journal":{"name":"Infection","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144475087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Applications of human lung organoids to human respiratory virus research: advances, limitations and future directions.","authors":"Qi Chen, Huaiqing Qi, Jun Guo","doi":"10.1007/s15010-025-02587-9","DOIUrl":"https://doi.org/10.1007/s15010-025-02587-9","url":null,"abstract":"<p><p>Human respiratory viruses (HRVs) can cause a spectrum of respiratory infections, which pose a significant challenge to global public health and are associated with a substantial economic impact. Traditional studies have often relied on in vitro culture systems utilizing transformed cell lines and animal models. However, there has been a shift towards emerging research models. Organoids are three-dimensional cell cultures that self-organize and differentiate into functional cell types, closely mimicking the structure and function of organs in vivo. Increasing evidence suggests that human lung organoids serve as reliable and effective models for studying HRVs. In this review, we compare common research models for HRVs, outline the establishment of human lung organoids, and explore their applications in HRV studies.</p>","PeriodicalId":13600,"journal":{"name":"Infection","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144475085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}